UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 1826, 2026

Silexion Therapeutics Corp
(Exact name of registrant as specified in its charter)

Cayman Islands	001-42253	N/A
(State or other jurisdiction	(Commission File Number)	(I.R.S. Employer
of incorporation)		Identification No.)

12 Abba Hillel Road Ramat-Gan, Israel		5250606
(Address of principal executive offices)		(Zip Code)

+972-3-756-4999

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Ordinary Shares, par value $0.0135 per share	SLXN	The Nasdaq Stock Market LLC
Warrants exercisable for Ordinary Shares at an exercise price of $1,552.50 per share	SLXNW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 28.0201 ~~Results~~Other ~~of Operations and Financial Condition~~Events.

OnFurther to its previous reports, as well as the approval of its shareholders received on May 185, 2026, on May 26, 2026, Silexion Therapeutics Corp, a Cayman Islands exempted company (“Silexion” or the “Company”) issued a press release announcing a prospective 1-for-10 reverse share split of all of its ~~financial~~issued ~~results~~and ~~for~~outstanding, ~~the~~and ~~first~~authorized but unissued, ordinary shares. The reverse share split will ~~quarter~~ become ~~ended~~effective ~~March~~after 31the close of the market on May 28, 2026., Aand ~~copy~~the ofCompany’s ordinary shares will begin trading on a reverse split-adjusted basis on the ~~press~~Nasdaq ~~release~~Capital isMarket ~~furnished~~at asthe ~~Exhibit~~open ~~99.1~~of ~~hereto~~the ~~and~~market ison ~~incorporated~~May by29, ~~reference~~2026. ~~into~~The ~~this~~ticker ~~Item~~symbol 2for the ordinary shares will remain “SLXN.~~02.~~”

The ~~information~~reverse ~~contained~~share insplit ~~this~~will ~~Item~~be ~~2.02~~effected ~~and~~automatically, ~~Exhibit~~without ~~99.1~~any ~~hereto~~action ~~shall~~required ~~not~~on bethe ~~deemed~~part toof bethe ~~“filed”~~Company’s shareholders. ~~for~~The ~~the purposes~~reverse ofshare ~~Section~~split 18will ofresult ~~the~~in ~~Securities~~a ~~Exchange~~corresponding ~~Act~~increase ofin ~~1934,~~the aspar ~~amended~~value (of the ~~“Exchange~~Company’s ~~Act”)~~ordinary shares, orfrom ~~otherwise~~$0.0135 ~~subject~~per share to ~~the~~$0.135 ~~liabilities~~per share. No fractional shares will be issued as a result of ~~such~~the ~~section~~reverse share split, ~~nor~~ as ~~will~~any ~~such~~fractional ~~information~~share betotals ~~deemed~~as ~~incorporated~~to bywhich ~~reference~~shareholders inwho ~~any~~are ~~filing~~DTC ~~under~~participants become entitled will be rounded up to the ~~Securities~~nearest ~~Act~~whole number of ~~1933,~~shares. asA ~~amended,~~copy orof ~~under~~the press release announcing the ~~Exchange~~reverse ~~Act,~~share ~~except~~split asis ~~may~~attached beas ~~expressly~~Exhibit ~~set~~99.1 ~~forth~~to this byreport ~~specific~~and ~~reference~~is inincorporated ~~such~~herein ~~filing~~by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release, dated May 1826, 2026~~, titled “Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update”~~

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SILEXION THERAPEUTICS CORP
Date: May 18, 2026	By:	/s/ Ilan Hadar
Date: May 26, 2026	By:	/s/ Ilan Hadar
	Name:	Ilan Hadar
	Title:	Chief Executive Officer

Filing Compare · Silexion Therapeutics Corp